Furthermore, treatment with the glucagon antagonist, LY2409021 over 6 months led to a significant increase in both ALT and hepatic fat fraction (HFF) compared to sitagliptin and placebo groups (53)
Tirzepatide activates GLP-1 and GIP receptors (dual incretin therapy)
Medicare, by law, is not allowed to cover medications for weight loss, but the Biden administration last year proposed reinterpreting the statute to allow coverage for the treatment of obesity as a chronic disease
therefore, the number of participants representing efficacy findings may differ from the number representing safety findings due to different pools of study participants analyzed for efficacy and safety
Advertisement When you take a GLP-1 medication, your body makes more GLP-1, which naturally decreases your appetite and makes you feel fuller
doi:10.1080/09513590802288259